The Abiraterone Dosing Chess Match With Johnson & Johnson-Back in Check

JAMA Oncol. 2021 Jun 1;7(6):827-828. doi: 10.1001/jamaoncol.2020.8087.

Authors

Russell Z Szmulewitz¹, Walter M Stadler¹, Mark J Ratain¹

Affiliation

¹ Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois.

PMID: 33662094
DOI: 10.1001/jamaoncol.2020.8087

No abstract available

MeSH terms

Androstenes* / adverse effects
Humans

Substances

Androstenes
abiraterone